No profile data available.
Geron Corporation (GERN) is a healthcare company in the blood disorder treatment drugs industry, based in Foster City, United States, with about 258 full-time employees.
It reported revenue of $183.88 million for fiscal year 2025, up 138.8% from fiscal year 2024, and net income of -$83.50 million. Its market capitalization was $787.03 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
Geron reported $183.88 million in revenue for fiscal year 2025, up 138.8% from $76.99 million in fiscal year 2024.
$787.03 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood disorder treatment drugs) include uniQure N.v. (QURE), Ultragenyx Pharmaceutical Inc. (RARE), Ardelyx, Inc. (ARDX), Rocket Pharmaceuticals, Inc. (RCKT).